Shares in Swedish biotech RhoVac were down 94% in mid-morning trading today after the company revealed a phase 2b trial of its prostate cancer vaccine RV001 showed it was no more effective than ...
Russia hits energy sector again, leaving many without power Biden denounces assault, says pressing forward with aid surge Hundreds of thousands without heating on Christmas Day 'What could be more ...
Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end of the programme ...